Key statistics
On Thursday, Guardant Health (GH*:MEX) closed at 538.12, -9.02% below its 52-week high of 591.47, set on Jul 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 538.12 |
---|---|
High | 538.12 |
Low | 538.12 |
Bid | -- |
Offer | -- |
Previous close | 483.41 |
Average volume | 0.00 |
---|---|
Shares outstanding | 123.02m |
Free float | 117.41m |
P/E (TTM) | -- |
Market cap | 3.09bn USD |
EPS (TTM) | -4.09 USD |
Data delayed at least 20 minutes, as of Aug 15 2024 12:30 BST.
More ▼
Press releases
- GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long
- Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
- Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy
- Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening
- Guardant Health to Participate in Upcoming Investor Conferences
- Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
- Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
- Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
- Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
More ▼